Intelligent bio solutions announces preliminary unaudited fiscal 2025 first quarter revenue results

Unaudited quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter higher-margin, recurring cartridge revenue expected to surpass reader revenue as primary driver expanded distribution network in saudi arabia new york, oct. 29, 2024 (globe newswire) -- intelligent bio solutions inc. (nasdaq: inbs) ("inbs" or the "company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary unaudited revenue results for the fiscal first quarter ended september 30, 2024. the company expects unaudited revenue of approximately $0.87 million for the three months ended september 30, 2024, representing an increase of 10% year-on-year and 20% quarter-on-quarter.
INBS Ratings Summary
INBS Quant Ranking